Titlebook: Oncologic Critical Care; Joseph L. Nates,Kristen J. Price Reference work 2020 Springer Nature Switzerland AG 2020 ICU.infectious diseases.

MAPLE

Esalate

Rapid Response Team (RRT) in Critical Careand a Joint Commission’s national patient safety goal. The aim of implementing RTT in any organizations was to improve patient safety and quality of care through identifying deterioration in patient status and intervening to stabilize the patient in a timely manner. Members of the RRT include multid

厚臉皮

Quality Assurance and Improvement in the Intensive Care Unitives were made after the Institute of Medicine published the report: To Err Is Human, in 2000. Although innumerous quality and safety initiatives have been implemented and some improvements in health care delivery and outcomes have been demonstrated, gaps still exist. This chapter will describe meth

鳴叫

Patient Risk Prediction Models. This refusal was advocated by some critical care colleges who stated patients with metastatic cancers would be poor candidates for intensive care unit (ICU) admission. More contemporaneously, tremendous advances in antitumor therapies have evolved, and critically unwell cancer patients have demon

龍蝦

Tidious

Role of the Clinical Pharmacist in the Oncologic Intensive Care Unitmented in the primary literature, with positive outcomes in areas such as adverse drug events, drug-drug interactions, antimicrobial therapy, anticoagulant therapy, sedation/analgesia therapy, and provision of advanced cardiac life support. Recent research has shown that the presence of clinical pha

凝視

jettison

GULF

Considerations for Medications Commonly Utilized in the Oncology Population in the Intensive Care Uncer therapies due to improved survival rates. The management of these patients is complex due to immunosuppression (from the malignancy and/or treatment), metabolic complications, and diverse medication regimens with the potential for significant drug-drug interactions and overlapping adverse effect

Innovative

Complications and Toxicities Associated with Cancer Therapies in the Intensive Care Unitmotherapy, including targeted therapies, immunotherapies, and cellular therapies. Currently, there are over 175 FDA-approved antineoplastic agents in the United States, many with a diverse and profound toxicity profile. Complications of antineoplastic therapy may result in the need for intensive car